Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/GW642444 once daily versus FP/salmeterol twice daily in persistent asthma
NL-OMON34054Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone, vilanterol, fluticasone propionate and salmeterol in persistent asthma and asthma (2 arms), sponsored by GSK. Primary endpoints: FEV1 0-4 hours and Trough FEV1. Started Oct 2010; status: active, not recruiting.
02
Drugs
fluticasonevilanterolfluticasone propionatesalmeterol
03
Conditions
persistent asthmaasthma
Beyond the preview
Go deeper on NL-OMON34054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34054.